Merck, NanoBio team on preclinical RSV deal

Tools

Ann Arbor, MI-based NanoBio Corporation said it's teaming up with an unnamed Merck subsidiary on preclinical development of an intranasal vaccine for Respiratory Syncytial Virus (RSV). Researchers will be studying a combination of Merck's RSV antigen with NanoBio's NanoStat adjuvant technology. "RSV remains a major cause of serious lung infections in children and the elderly," said NanoBio founder and CEO James Baker, Jr. in a statement. "We look forward to working together in an effort to advance RSV vaccine research." NanoBio release

Comments